Efficacy and Predictors of Response to a Low‐FODMAP Diet in Patients With Overlap of Functional Dyspepsia and Irritable Bowel Syndrome: A Prospective Multicentre Randomized Clinical Trial
BACKGROUND AND AIMS: Functional dyspepsia (FD) frequently coexists with irritable bowel syndrome (IBS), resulting in a complex clinical phenotype characterized by prominent postprandial symptoms and limited treatment options. We compared the efficacy of a low-fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet with traditional dietary advice (TDA) in this population. METHODS: In this multicentre randomized, assessor-blinded trial, adults fulfilling Rome IV criteria for both FD and IBS were assigned to a low-FODMAP diet (LFD) or TDA for 6 weeks, with structured dietitian support. The primary endpoint was a combined response, defined by both a ≥ 50-point reduction in IBS Symptom Severity Scale and a ≥ 30% reduction in Short-Form Nepean Dyspepsia Index (SFNDI) symptom scores at 6 weeks. Among patients who responded to LFD, FODMAPS were systematically reintroduced from 7 to 12 weeks, and patients who had symptom recurrence were defined as 'true responders'. Baseline predictors of true LFD response were evaluated using univariable and multivariable logistic regression (CTRI/2025/04/084483). RESULTS: A total of, 112 participants were randomized (LFD, n = 59; TDA, n = 53; mean age 40.9 ± 15.2 years, 42.8% males). After 6 weeks, the combined IBS-FD response rates were 59.3% versus 32.1% (p = 0.005) in the LFD and TDA arms respectively. After FODMAP reintroduction, 32/35 patients (91.4%) had symptom recurrence (true responders). Improvements in symptom and disease-specific quality-of-life scores favoured LFD. Exploratory multivariable predictors of response to LFD were postprandial distress sub-type and a higher (worse) baseline SF-NDI quality-of-life score. CONCLUSION: A low-FODMAP diet was superior to traditional dietary advice in improving global symptoms and HRQoL in patients with FD-IBS overlap, supporting targeted fermentable carbohydrate restriction as an effective, personalized therapeutic strategy.
Authors
- Ashok Dalal (ORCID: https://orcid.org/0000-0001-7590-2226)
- Vaishali Bhardwaj (ORCID: https://orcid.org/0000-0001-6473-5581)
- Riya Khurana
- Manjeet Kumar Goyal (ORCID: https://orcid.org/0000-0002-5511-2099)
- Sanjeev Sachdeva (ORCID: https://orcid.org/0000-0002-5588-1111)
- Omesh Goyal (ORCID: https://orcid.org/0000-0002-6347-0988)
- Venkatesh Sudharsan Vaithiyam (ORCID: https://orcid.org/0000-0002-0713-5501)
- Gurseen Rakhra (ORCID: https://orcid.org/0000-0002-0618-6278)
Institutions
- Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital (IN)
- Dayanand Medical College & Hospital (IN)
- Govind Ballabh Pant Hospital (IN)
- Cleveland Clinic Akron General (US)
- Manav Rachna International Institute of Research and Studies (IN)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1111/apt.71100
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00